 | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from rat) |
| Target | CD52 |
| Clinical data | |
| Trade names | Campath, Mabcampath, Lemtrada, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a608053 |
| License data |
|
| Pregnancy category | |
| Routes of administration | Intravenous infusion |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Elimination half-life | ~288 hrs |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C6468H10066N1732O2005S40 |
| Molar mass | 145454.20 g·mol−1 |
  (what is this?) (verify) | |
Alemtuzumab, sold under the brand names Campath and Lemtrada among others, is a medication used to treat chronic lymphocytic leukemia and multiple sclerosis.[8] In chronic lymphocytic leukemia, it has been used as both a first line and second line treatment.[8] It is given by injection into a vein.[8]
It is a monoclonal antibody that binds to CD52, a protein present on the surface of mature lymphocytes, but not on the stem cells from which these lymphocytes are derived. After treatment with alemtuzumab, these CD52-bearing lymphocytes are targeted for destruction.
Alemtuzumab was approved for medical use in the United States in 2001.[8] (Mab)Campath was withdrawn from the markets in the US and the EU in 2012, to prepare for a higher-priced relaunch of Lemtrada aimed at multiple sclerosis.[9]
- ^ "Alemtuzumab Use During Pregnancy". Drugs.com. 22 August 2022. Retrieved 6 January 2024.
- ^ "TGA eBS - Product and Consumer Medicine Information Licence".
- ^ "TGA eBS - Product and Consumer Medicine Information Licence".
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
- ^ "Campath- alemtuzumab injection". DailyMed. 3 May 2023. Retrieved 6 January 2024.
- ^ "Lemtrada- alemtuzumab injection, solution, concentrate". DailyMed. 23 May 2023. Retrieved 6 January 2024.
- ^ "Lemtrada EPAR". European Medicines Agency. 12 September 2013. Retrieved 6 January 2024.
- ^ a b c d "Alemtuzumab Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 15 July 2019.
- ^ Cite error: The named reference
ptwas invoked but never defined (see the help page).